Measles is rising again worldwide despite effective vaccines. This article explains the data behind the resurgence, including vaccine coverage gaps, outbreaks, hesitancy, and post-COVID disruption.
Epidemiologists have found that recent Ebola outbreaks may be linked to the virus re-emerging from human survivors rather than from wildlife. The virus can persist in immune-protected sites, notably semen, for months. A significant percentage of survivors experience long-term health effects, necessitating continued surveillance and testing for ongoing transmission risks.
The measles virus, believed to have evolved from rinderpest, has a rich historical context with significant developments in understanding and vaccination. Despite vaccination efforts dramatically reducing mortality, recent outbreaks in regions like Bangladesh illustrate the importance of maintaining high vaccination coverage. Measles remains a serious threat, highlighting past lessons and current challenges.
How many people are affected by TB worldwide? In 2024, an estimated number of 10.7 million people worldwide were infected
Introduction: The Mathematical Mystery Tuberculosis (TB) is considered one of the deadliest infectious diseases in the world. According to a
Ebola vaccine development has made major progress, moving from experimental research to licensed vaccines and real-world outbreak control. Yet important challenges remain, including limited protection across all Ebola species, uncertain durability of immunity, and the difficulty of testing vaccines during unpredictable outbreaks.
A new Ebola outbreak linked to the rare Bundibugyo strain has emerged in the Democratic Republic of Congo and Uganda, prompting the World Health Organization to declare a public health emergency. With rising suspected cases, deaths, and concerns over cross-border transmission, health authorities are intensifying surveillance, testing, and containment efforts across the region.
Haemorrhagic Fever with Renal Syndrome (HFRS) has historical roots in ancient texts and was notably recognized during the Korean War in the 1950s. The Hantaan virus was isolated in the 1970s, and various hantaviruses have since emerged globally. HFRS significantly affects Asian countries, with a 1-15% mortality rate, while Hantavirus Pulmonary Syndrome (HPS) has a 35-50% fatality rate.
Learn about Hantavirus (HTNV), including the differences between HFRS and HPS. Discover transmission risks, global fatality rates, and the latest diagnostic methods in our comprehensive guide.
Norovirus was first identified in 1968 during an AGE outbreak in Ohio, later characterized and sequenced in the early 1990s. It causes significant illness globally, particularly in developing regions. Challenges for vaccine development include the virus’s genetic diversity and lack of reliable culture systems. Current research focuses on candidate vaccines targeting multiple genotypes.